Slattery WH III, Schwartz MS, Fisher lM, Oppenheimer M. Acoustic
neuroma surgical cost and outcome by hospital volume in California.
Otolaryngology Head Neck Surgery 2004; 130:726-35. 
Slattery WH III, Fisher lM, Iqbal Z, Oppenheimer M. Vestibular
schwan noma growth rates in neurofibromatosis type" natural history
consortium subjects. Otol NeurotoI2004;25(5):811-7.
Slattery WH III, Fisher lM, Iqbal Z, Liu, N. Oral steroid
regimens for idiopathic sudden sensorineural hearing loss.
Otolaryngology Head Neck Surgery 2005;132(1);5-10.
Slattery WH III, lev MH, Fisher, lM, Connell SS, Iqbal Z, Go Jl.
MRI evaluation of neurofibromatosis type II patients: A standardized
approach for accuracy in interpretation. Otol Neurol, 2005; 26:733-740.
Slattery WH III, Fisher lM, Iqubal Z, Friedman RA, Liu N.
Intratympanic steroid injection for treatment of idiopathic sudden
hearing loss. Otolaryngology Head and Neck Surgery, 2005;133:251-259.
Slattery WH, Fisher lM, Hitselberger W, Friedman RA, Brackmann D.
Hearing preservation surgery for neurofibromatosis Type 2-related
vestibular Schwannoma in pediatric patients. J Neurosurg:Peds. 2007;
106:255-260.
Fisher LM, Doherty JK, Lev MH, Slattery WH Distribution of
nonvestibular cranial nerve Schwannomas in neurofibromatosis 2. Otol &
Neuroto/28:1083-1090, 2007.
Evans DG, Kalamarides M, Hunter-Schaedle K, Blakeley J, Slattery
WH, et al. Consensus recommendations to accelerate clinical trials for
neurofibromatosis type 2. Clin Cancer Res 2009; 15(16):5032-5039.
Fisher lM, Doherty JK, lev MH, Slattery WH III. Concordance of
bilateral vestibular schwannoma growth and hearing changes in
neurofibromatosis 2: NF2 Natural History Consortium. Otology &
Neurotology, 2009 (in press).
Rauch, SD, Reda 0 , Halpin CF, Antonellit PJ, Babu S, Carey JP, Gantz BJ, Goebel JA, Hammerschlag PE, Harris JP, Isaacson B, Lee D, Linstrom CJ, Parnes, lS, Shi H, Slattery WH, et al. Oral vs Intratympanic Corticosteroid Therapy for Idiopathic Sudden Sensorineural Hearing Loss. (Submitted to NEJM). August 2010.
